EZH2 and hematologic disorder: These studies suggest that bromodomain inhibitors alone and the combination of bromodomain inhibitor and JAK2 inhibitor can be a novel therapeutic strategy for eradicating hematologic malignancies harboring EZH2 mutation [127,130].